Tech Company Financing Transactions
Chroma Therapeutics Funding Round
Chroma Therapeutics, based in Oxon, secured $18.9 million in funding from The Wellcome Trust and Abingworth.
Transaction Overview
Company Name
Announced On
6/14/2004
Transaction Type
Venture Equity
Amount
$18,914,200
Round
Series B
Investors
The Wellcome Trust (Lead Investor)
Proceeds Purpose
The new funds will enable Chroma to accelerate the development of its pipeline of small molecule oncology drugs targeted against chromatin-modifying enzymes.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
93 Milton Park
Oxon, OX14 4RY
UK
Oxon, OX14 4RY
UK
Phone
Website
Email Address
Overview
Chroma Therapeutics is a privately-held biotechnology company focused on the discovery and development of novel small molecule drugs based upon chromatin biology.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Peter Allen
Chief Executive Officer
Richard Bungay
Chief Medical Officer
Martin Toal
Browse more venture capital transactions:
Prev: 6/14/2004: Cellular Genomics venture capital transaction
Next: 6/14/2004: Hands-On Mobile venture capital transaction
Share this article
News on VC Transactions
We do our best to record funding rounds that are announced publicly. VC transactions reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs